Mumpsvax

Uses

Active immunisation against mumps

Dosage

Mumpsvax dosage

Active immunisation against mumps-

• Adult:0.5 mL as a single dose via SC admin, preferably into the outer aspect of the upper arm.
• Child:Given as a combination with measles and rubella vaccines: ≥12 mth: 2 doses of 0.5 ml via IM admin (SC admin if there is bleeding disorder). 1st dose is usually given after 1st birthday (recommended age: 12-15 mth) and 2nd dose at 3-5 yr or prior to school entry. Doses should be separated by at least 4 wk. May be given at any age if routine admin has been omitted. Immunisation dose given before 12 mth of age may not be effective long term and patients should be revaccinated with the 2 dose schedule.

Side Effects

Skin rashes, pharyngitis, fever, and lymphadenopathy; arthralgia and arthritis may occur.

Precaution

Women of child-bearing age should be vaccinated if they are seronegative; those who are found to be seronegative during pregnancy should be vaccinated in the early postpartum period. Not advisable to become pregnant within 1 mth of vaccination. Not recommended for children <1 yr. Allow alcohol or disinfectant that is used for skin cleansing to evaporate before vaccination to prevent inactivation of live vaccines. Bleeding disorders (use SC route).

Interaction

Not to be given within 1 mth of admin of other live vaccines. Live vaccines should only be given at least 3 wk before or 3 mth after the use of immunoglobulin. Avoid admin during immunosuppressant or high dose systemic corticosteroid therapy.

Pregnancy & Breastfeeding use

Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Contraindication

Pregnancy. Hypersensitivity. Severe primary immunodeficiency; current treatment with chemotherapy or radiotherapy and within 6 mth of stopping such therapy; solid organ transplant patients receiving immunosuppressants, bone marrow transplant and for at least 12 mth after stopping immunosuppressive therapy, patients on high-dose systemic corticosteroids, HIV patients with immunosuppression.

Storage Condition

Store at 2-8° C. After reconstitution, discard if not used within 8 hr.

Innovators Monograph

You find simplified version here Mumpsvax